



NDA 217500
NADA N-141-561

**DEEMED GRANTED -
MEDICAL GAS CERTIFICATION REQUEST**

Absolute Air, LLC
Attention: Randy Ritter
Site Manager
1305 40th Street NW
Faribault, MN 55021

Dear Randy Ritter:

Please refer to your April 11, 2022, request, received on April 11, 2022, for certification of Oxygen, USP as a designated medical gas. You have requested to market Oxygen, USP, for human and animal use.

A request for certification of a medical gas as a designated medical gas submitted under section 575(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is deemed to be granted unless, within 60 days of the filing of the request, FDA finds that one or more of the bases for denying the request listed at section 575(a)(2) of the FD&C Act applies. FDA has made no such finding in connection with your request, and 60 days have passed since your request was filed. Accordingly, by operation of section 575(a)(2) of the FD&C Act, your request for certification of Oxygen, USP, as a designated medical gas is deemed to be granted, and you now have in effect an approved new drug application (NDA 217500) and an approved new animal drug application (NADA N-141-561) for this gas effective June 10, 2022.

If any of the information you have submitted in connection with your request changes, such as where the gas is manufactured or changes in applicant information, you will need to submit an updated certifications request to these same NDA/NADA application numbers. Please consult section IV.D of the draft guidance document entitled Certification Process for Designated Medical Gases (available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332136.pdf>) for additional information. Please cite the NDA/NADA application numbers listed above at the top of the first page of any communications concerning these applications.

We encourage the submission of Designated Medical Gas submissions electronically via the CDER NextGen Portal located here: <https://edm.fda.gov/EDMIDPLogin/welcome>. If you choose to instead submit your application in paper, send the paper submissions, including those sent by overnight mail or courier, to the following address:

NDA 217500
NADA N-141-561
Page 2

Central Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705

Please do not mail any paper copies of submissions that are submitted via the CDER NextGen Portal.

If you have any questions, please contact Elisa Nickum, Regulatory Business Process Manager, at (301) 796 - 4226 or elisa.nickum@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Charles J. Andres, Ph.D.
Director, Division of Business Information Science and Management
Office of New Animal Drug Evaluation, HFV-180
Center for Veterinary Medicine
FDA

Michael M. Folkendt
Associate Director for Regulatory Affairs
Office of Program and Regulatory Operations
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research
FDA



Charles
Andres

Digitally signed by Charles Andres

Date: 6/08/2022 07:51:31AM

GUID: 6245d93a002dbcec7f526c5ea3b4308c



Michael
Folkendt

Digitally signed by Michael Folkendt

Date: 6/07/2022 06:01:37PM

GUID: 508da7230002a1fa8802aba375f7bc0d